Epoxy Resin System Integration Patent Landscape 2026
- Filing activity has already peaked. 2022 recorded 11 families, the high point of the whole 2015–2026 window, with nothing in the pipeline suggesting a second wave.
- The corpus is polymer-chemistry-led, not device-led. C08L (polymer compositions) touches all 44 families and C08G (condensation polymers) touches 30, while H01L (semiconductor devices) appears in only 13 — the claims are being written as resin chemistry first.
- Europe leads on where these families are filed. EPO received 8 of the tracked filings, ahead of the United States (7), Japan (6) and China (5), a filing-office spread worth checking before assuming this is a US-centric art.
Filing growth compares 2021 (1 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 44 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Epoxy resin system integration sits at the junction of polymer formulation and packaging or structural assembly — encapsulating semiconductor devices, co-curing into a composite matrix, or bonding layered laminates. This dataset pulls 44 patent families published between 2015 and 2026 whose claims combine epoxy resin chemistry (title/abstract) with electronic encapsulation, composite matrix integration or co-cure integration (title/claims/description), narrowed further by IPC classes covering semiconductor packaging, plastics shaping and polymer compositions.
Because publication trails filing by roughly 18 months, the 2025 and 2026 counts in any trend chart understate real activity; treat the last one to two years as a floor, not a ceiling.
Filing trend and technology mix
Two views matter here: whether the field is still gaining filers, and which IPC subclasses actually carry the claim weight.
A flat-to-declining trend after a 2022 peak
Filings were at zero in 2017, rose to a peak of 11 families in 2022, and the midpoint of the series sits at that same 2022 figure — a signature of a field that expanded, crested, and has not built a second wave. Read the final one or two years as undercounted given publication lag, but the shape from 2018 to 2022 is a genuine rise-then-plateau, not an artefact of the cut-off.
Polymer chemistry dominates over device claims
C08L (polymer compositions) appears in every one of the 44 families and C08G (condensation polymers) in 30, while H01L (semiconductor devices) reaches only 13. Shaping and layering classes — B29C, B32B — barely register at 2 apiece. The claim activity is concentrated in the resin system itself, with device-level integration treated as a downstream application rather than the locus of invention.
Shares are the percentage of the 44 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Epoxy Resin System Integration with Eureka
This page is one run against one query. Ask Eureka your own question about epoxy resin system integration and every answer comes back with the patent numbers behind it.
Try EurekaThe records other filings build on
USH1405H1 — Epoxy resin composition
An epoxy resin composition with a finely dispersed elastomeric block copolymer phase — a hydrogenated conjugated diene block joined to a carboxylated monoalkenyl aromatic hydrocarbon block. The copolymer is emulsified from a non-polar solvent (e.g. tetrahydrofuran) by gradual addition of a polar solvent (water or alcohol) before blending into the epoxy resin, yielding dispersed rubber particles averaging 0.05–0.20 microns in diameter.Filed by Shell Oil Company, published 1995-01-03 as a statutory invention registration.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6207786B1 | Ternary systems of benzoxazine, epoxy, and phenolic resins | 267 |
| 2 | US20050065294A1 | Electrically insulative powder coatings and compositions and methods for making them | 52 |
| 3 | WO2000027921A1 | Ternary systems of benzoxazine, epoxy, and phenolic resins | 44 |
| 4 | US4689389A | Curable liquid compositions of epoxy-and mercaptan-terminated polymers | 22 |
| 5 | EP0171198A1 | Curable liquid compositions of epoxy- and mercaptan-terminated polymers | 15 |
| 6 | US9631049B2 | Agents for reworkable epoxy resins | 12 |
| 7 | EP0565206A2 | Epoxy resin composition | 11 |
| 8 | CN102276797A | 一种具有优良温度循环性能的环氧树脂组合物及其制备方法 | 8 |
| 9 | US20060074149A1 | Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom | 7 |
| 10 | EP2736999B1 | Flexible bismaleimide, benzoxazine, epoxy-anhydride adduct hybrid adhesive | 5 |
Citation counts inside this searched corpus favour older filings by construction — read them as a signal of historical influence on ternary and mercaptan-cure chemistry, not as a ranking of current commercial relevance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers imply for a filing decision
Three read-throughs matter for anyone deciding where to place claims next: the trend shape, the classification skew, and the geographic spread.
The wave has already crested
Growth from 2017's zero to an 11-family peak in 2022, followed by a flat-to-declining tail, points to a technology that had its land-grab and is now in maintenance mode rather than expansion. New entrants filing broad composition claims now are filing into occupied space.
Chemistry, not packaging, is where claims sit
Every tracked family touches C08L and 30 touch C08G, against only 13 in H01L. Filers are securing the resin formulation first and treating the encapsulation or composite end-use as an application example rather than the inventive core.
Europe edges the United States as filing venue
EPO's 8 filings lead a spread that includes the US (7), Japan (6), China (5), WIPO/PCT (4) and the UK (3) — no single office dominates, so freedom-to-operate work has to clear multiple jurisdictions rather than one home market.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to epoxy resin system integration, with the prior art for and against each one.
Who holds the claim space, and where it's thin
The assignee list is a long tail: legacy names like Dow, Morton Thiokol, Toyobo and Toyobo MC, Thiokol Chemicals and Edison Polymer Innovation show zero filings in the latest year, consistent with the field's flat-to-declining trend rather than any single company retreating.
Ternary benzoxazine-epoxy-phenolic systems
The most-cited record in the corpus, and its WO counterpart at 44 citations, both cover ternary benzoxazine/epoxy/phenolic resin systems — a formulation family that still anchors citation patterns even though it predates the 2015 filing window.
Electrically insulative powder coatings
US20050065294A1 sits well behind the ternary systems on citations but well ahead of everything else, marking powder-coating insulation as a second distinct cluster of influence separate from the mercaptan-cure and benzoxazine lines.
Epoxy-mercaptan curable liquid systems
US4689389A and its EP counterpart EP0171198A1 cover curable liquid compositions combining epoxy- and mercaptan-terminated polymers — an older cure chemistry still cited by newer encapsulation and co-cure filings.
| Assignee | Recent year | YoY |
|---|---|---|
| Dow Chemical Company | 0 | — |
| MORTON THIOKOL LTD | 0 | — |
| Toyobo Co., Ltd. | 0 | — |
| Toyobo MC Corporation | 0 | — |
| THIOKOL CHEMICALS LTD | 0 | — |
| Edison Polymer Innovation Corporation | 0 | — |
| Tianjin Kaihua Insulating Materials Co., Ltd. | 0 | — |
| Shell International Research Maatschappij B.V. | 0 | — |
Where to take this
The dataset points to a mature, chemistry-first claim landscape with specific gaps on the device-integration side.
Check freedom-to-operate against the resin claims first
With 44 of 44 families touching C08L, any new filing needs clearance against polymer-composition claims before device-integration claims, not after.
Run a claim-clearance search in Eureka →Watch the device-side white space
H01L coverage sits at only 13 of 44 families — device-level integration claims (die-attach cure profiles, fine-pitch encapsulant behaviour) remain comparatively open.
Explore white space mapping in Eureka →Common questions on this landscape
The trend is flat to declining rather than active. Filings rose from zero in 2017 to a peak of 11 families in 2022, and the midpoint of the whole 2015–2026 series is that same 2022 figure, which is the statistical signature of a field that has already crested. The most recent one to two years will look artificially low because publication lags filing by roughly 18 months, but the shape of the rise-then-plateau predates that lag effect and is a genuine finding, not a cut-off artefact. New filers should expect to be working into occupied claim space rather than an expanding frontier.
C08L (polymer compositions) and C08G (condensation polymers) carry almost all the weight, appearing in 44 and 30 of the 44 tracked families respectively. H01L (semiconductor devices) appears in only 13, and shaping/layering classes like B29C and B32B barely register at 2 each. This means the inventive core of most filings is the resin chemistry itself, with electronic encapsulation or composite integration treated as an applied use case rather than the subject of the primary claim.
Start with the C08L and C08G classifications, since every family in this corpus touches the former and most touch the latter — that is where the dense prior art sits. The most-cited records, including the ternary benzoxazine-epoxy-phenolic systems and the epoxy-mercaptan curable liquid compositions, are older filings that still shape citation patterns in this space, so they are worth checking even though they predate the 2015 window. Only after clearing the resin-composition layer does it make sense to check the thinner H01L device-integration layer.
USH1405H1 is a statutory invention registration from Shell Oil Company, published in 1995, covering an epoxy resin composition with a finely dispersed elastomeric block copolymer phase made by a specific emulsification process — non-polar solvent dispersal followed by gradual polar solvent addition, yielding rubber particles of 0.05–0.20 microns. It blocks that particular combination of copolymer structure, emulsification method and particle-size range, not epoxy-elastomer blends generally. A formulation using a different dispersal method, a different block chemistry, or particle sizes outside that stated range sits outside its literal claim scope, though it remains a relevant citation for anyone patenting rubber-toughened epoxy systems.
The European Patent Office leads with 8 of the tracked filings, ahead of the United States at 7, Japan at 6, China at 5, the PCT route at 4, and the United Kingdom at 3. No single office accounts for even a fifth of total filings, so this is not a US-centric or China-centric art in the way many polymer technologies are. A clearance or filing strategy built around only one or two jurisdictions would miss a meaningful share of the documented activity.
Research Epoxy Resin System Integration in depth with Eureka
Go past this page: query the whole epoxy resin system integration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.